AXNX earnings

MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or $0.34 per share (EPS), compared to $126 million or $0.09 per share a year ago and achieved adjusted3 EPS of $0.55 for the period, compared to $0.45 a year ago.

Generated quarterly revenue of $93.1 million, an increase of 32% year over year Fiscal year 2023 revenue guidance increased to $362 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. "Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based on the s

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 3Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 3Q23 webcast. A replay of the webcast will be archived in t

Generated quarterly revenue of $92.9 million, an increase of 35% year over year Fiscal year 2023 revenue guidance increased to $358 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2023. "Our commercial team continues to execute at a high level, generating revenue growth of 35% year over year in the second quarter," said Raymond W. Cohen, chief executive officer. "Our growth was driven by higher utilization and share of wallet at existing customers and the onboarding of new accounts. Based

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2023 financial results after the close of trading on Thursday, July 27. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 2Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 2Q23 webcast. A replay of the webcast will be archived in the Events sec

Generated quarterly revenue of $70.7 million, an increase of 46% year over year Fiscal year 2023 revenue guidance increased to $348 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2023. "Our commercial team continues to execute at a high level, generating revenue growth of 46% year over year in the first quarter," said Raymond W. Cohen, chief executive officer. "Our sacral neuromodulation growth was driven by higher utilization and share gains while Bulkamid® continues to benefit from ph

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 1Q23 registration. For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 1Q23 webcast. A replay of the webcast will be archived in the Ev

Generated record quarterly revenue of $86 million, an increase of 62% y/y Reported fiscal year 2022 revenue of $274 million, an increase of 52% y/y Reiterated fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2022. "This quarter's record results reflect the growing demand for our best-in-class incontinence products," said Raymond W. Cohen, chief executive officer of Axonics. "Our U.S. commercial team is cont

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter 2022 financial results after the close of trading on Wednesday, March 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties may join the conference call by telephone by registering at the following link: Axonics 4Q22 registration. After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone. For those not planning to ask a question on the

4Q22 total company net revenue expected to be $85.6 to $86.0 million, an increase of 61% y/y Fiscal year 2022 total company net revenue expected to be in the range of $273.6 million, an increase of 52% y/y Fiscal year 2023 revenue guidance of $342 million, an increase of 25% y/y Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fiscal year ended December 31, 2022 and issued fiscal year 2023 revenue guidance. "This quarter's record revenue result reflects the growing demand for our best-in-class incontinence products

Generated record quarterly revenue of $70 million, an increase of 50% year over year Fiscal year 2022 revenue guidance raised to $262 million, an increase of 45% year over year Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2022. "This quarter's record revenue result reflects growing demand from physicians and their patients for our best-in-class incontinence products," said Raymond W. Cohen, chief executive officer of Axonics. "In the third quarter, total revenue increased by 50% compared to

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2022 financial results after the close of trading on Monday, October 31. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: Axonics 3Q22 registration. After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone. For

Generated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21 Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal year 2021 Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2022. "This quarter's record revenue result reflects the growing demand for our best-in-class incontinence solutions," said Raymond W. Cohen, chief executive officer of Axonics. "Sacral neuromodulation revenue grew 39% year over year, benefiting from t

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report second quarter 2022 financial results after the close of trading on Monday, August 1. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. Interested parties that would like to join the conference call by telephone are required to register in advance by visiting the following link: Axonics 2Q22 registration. After registering, a confirmation email will be sent that includes the dial-in number and unique access code required to join the conference call by telephone. For t

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended March 31, 2022. "We are pleased with this quarter's revenue result considering the significant impact the Omicron surge had on elective procedures in January and February," said Raymond W. Cohen, chief executive officer of Axonics. "Sacral neuromodulation procedure volumes recovered nicely in March and continued to trend favorably in April. Bulkamid® generated yet another quarter of record revenue and we are delighted to report that over 32,000 women have had the

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2022 financial results after the market closes on Thursday, May 5, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 6152315. A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be available

Total revenue of $53.1 million in 4Q21, an increase of 53% year over year Fiscal year 2022 revenue outlook of $234 million, an increase of 30% year over year Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months and fiscal year ended December 31, 2021. "We are proud of our fourth quarter and fiscal year 2021 results considering the disruption Covid-19 has had on elective procedures in the U.S. and around the world," said Raymond W. Cohen, chief executive officer of Axonics. "In 2021, in addition to strong commercial exe

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report fourth quarter and fiscal year 2021 financial results after the market closes on Thursday, February 24, 2022. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 6189042. A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the we

Quarterly revenue exceeds $50 million for the first time Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended December 31, 2021. 4Q21 total company net revenue is expected to be in the range of $52.9 to $53.3 million, an increase of 53% compared to $34.8 million in the prior year period. 4Q21 sacral neuromodulation (SNM) net revenue is expected to be in the range of $44.2 to $44.4 million, an increase of 27% compared to $34.8 million in the prior year period. 4Q21 Bulkamid® net

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the third quarter ended September 30, 2021. "We are pleased with this quarter's revenue result considering the significant impact the surge in Covid-19 Delta variant cases had on elective procedure volumes in August and September, in addition to staffing shortages at hospitals and seasonality from summer vacations," said Raymond W. Cohen, chief executive officer of Axonics. "Bulkamid® posted its highest revenue quarter to date and has proven to be more insulated from Covid-19 impact du

Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, will report third quarter 2021 financial results after the market closes on Thursday, November 4, 2021. In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time. Interested parties may access the live conference call by dialing 866-687-5771 (U.S.) or 409-217-8725 (international) and using passcode 8798817. A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. A replay of the webcast will be avai

Total revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million Bulkamid® revenue of $5.7 million in first full quarter since acquisition Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million Axonics, Inc. (NASDAQ:AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021. "This quarter's record revenue result reflects the growing demand for our best-in-class incontinence solutions," said Raymond W. Cohen, chief executive officer of Axonics. "Clinical outcomes and satis